Mapping theFuture ofPsychedelicNeuroscience

Psychedelic research, claim by claim. See what studies found, where they disagree, and what remains uncertain.

Request a briefingRead the evidence
Depression patients1 of 2: Baseline
Schematic. The stages are the timepoints Daws 2022 measured; nothing here encodes a magnitude.

Every chip links to its claim and sources.

Where the evidence stops

From molecule to clinic, link by link.

Psilocybin beside two shorter-acting candidates. Each link is a quoted result, a statement with no measurement, or a gap. Pick who was studied to see where that kind of evidence appears.

Who was studied

  • Key: publishedpublished
  • Key: statedstated
  • Key: missingmissing
  • Key: not applicablenot applicable
MoleculeExposureShort-term benefitMonths laterCare and safety
Psilocybin (reference)
GH001, inhaled 5-MeO-DMT
SPL026, IV DMT

Stress-tested, in public

Psilocybin for depression: what holds under pressure.

The published analysis, re-run and stressed against two thresholds. A row is stable when its whole interval shows more benefit than the threshold, and sensitive when the interval straddles it.

Hedges' g with 95% intervals; negative favours psilocybin. Dashed line: −0.24. Dotted line: −0.50. Solid line: no effect.

  • Primary model (SYPRES, pinned)−0.90 [−1.26, −0.55]−0.24: stable−0.50: stable
  • Double-blind trials only (as reported)−0.81 [−1.03, −0.60]−0.24: stable−0.50: stable
  • MDD or TRD only−0.93 [−1.87, 0.01]−0.24: sensitive−0.50: sensitive

Awaiting independent review. Request the two-page brief and its reviewer packet

Leaving out one trial at a time moves g between −0.95 [−1.29, −0.61] (without Rosenblat 2024) and −0.81 [−1.07, −0.55] (without Davis 2021).

SYPRES's 9 other subgroup and sensitivity analyses
  • Exclude high RoB−0.97 [−1.38, −0.57]−0.24: stable−0.50: stable
  • Parallel design−0.80 [−1.11, −0.49]−0.24: stable−0.50: sensitive
  • Crossover or open-label extension−1.04 [−2.06, −0.03]−0.24: sensitive−0.50: sensitive
  • Expanded inclusion criteria−0.88 [−1.21, −0.56]−0.24: stable−0.50: stable
  • Excluding outliers−0.81 [−1.07, −0.55]−0.24: stable−0.50: stable
  • Fixed Effects model−0.84 [−1.02, −0.67]−0.24: stable−0.50: stable
  • Alternate dosing in Goodwin 2022−0.87 [−1.27, −0.47]−0.24: stable−0.50: sensitive
  • Clinician-rated outcomes−1.02 [−1.60, −0.44]−0.24: stable−0.50: sensitive
  • Self-report outcomes−1.00 [−1.68, −0.31]−0.24: stable−0.50: sensitive
Months later: Goodwin 2022, one trial, unpooled
  • Endpoint score, the time model's measure, Week 9−0.46 [−0.78, −0.15]−0.24: sensitive−0.50: sensitive
  • Change from baseline, Week 9−0.28 [−0.59, 0.04]−0.24: sensitive−0.50: sensitive
  • Response, Week 9−0.35 [−0.79, 0.09]−0.24: sensitive−0.50: sensitive
  • Remission, Week 9−0.37 [−0.86, 0.11]−0.24: sensitive−0.50: sensitive
  • Endpoint score, the time model's measure, Week 12−0.41 [−0.73, −0.10]−0.24: sensitive−0.50: sensitive
  • Change from baseline, Week 12−0.24 [−0.55, 0.07]−0.24: sensitive−0.50: sensitive
  • Response, Week 12−0.50 [−0.92, −0.08]−0.24: sensitive−0.50: sensitive
  • Remission, Week 12−0.57 [−1.04, −0.10]−0.24: sensitive−0.50: sensitive
  • Sustained response, week 3 to week 12, Week 3-12 Sustained Response−0.62 [−1.17, −0.07]−0.24: sensitive−0.50: sensitive

An assumed bias toward benefit, added to every trial. An assumption, not an estimate.

Assumed bias 0.00Band R1
Primary model (SYPRES, pinned): g −0.90 [−1.26, −0.55]−0.24: stable−0.50: stable

Stability at −0.24 ends at an assumed bias just above 0.31; at −0.50, just above 0.05.

Awaiting independent review. Request the two-page brief and its reviewer packet

Living evidence

A living evidence grid.

Each card’s counts are computed from a synthesis that rescans the citation graph every week; its tiers and readings are editorial judgments. Claims carry their tier, the research programs behind them, and what would change them.

Living synthesisVersion 2.1Updated 2026-10-05

Psilocybin (single dose)

Does one dose of psilocybin rewire the brain?

Ask ten studies whether one dose of psilocybin rewires the brain and you get different answers. Read side by side, much of the disagreement lines up with who was dosed, what was measured and which species, though dose, setting and timing differ too.

Reads 9 of 39

30 citation-linked works not yet read

7 programs

research groups by authorship, across 10 sources

13 claims

and 9 relations, each tiered with its reason

2026-09-28

last citation-graph scan; it reruns weekly

Open the synthesisHow much to trust this
Our interpretation

The open question it raises

Is durable human “rewiring” specific to the depressed brain (a marker of clinical response) rather than a general property of the drug?

A reading offered to the field as a question rather than asserted as fact. Tested against 9 of the 10 studies here; not yet re-tested with the rest.

2 automated stress tests. Expert review: invited.

Offer to review it
Healthy volunteersPreliminary

In healthy volunteers, a single 25 mg dose left enduring functional brain changes “largely absent” one month later, though some diffusion-imaging and network-modularity signals persisted; what lasted was mainly psychological: well-being and insight.

Would change ifA pre-registered, adequately powered study in healthy volunteers finds enduring functional brain change at one month or later. That would move this from preliminary to active debate; an independent replication of the null would move it toward established.

Claim 1 in full
Depression patientsPreliminary

In depression patients given two doses with psychological support, psilocybin increased global brain integration (lower network modularity), and the size of that change tracked the antidepressant response.

Would change ifAn independent research program fails to find increased global integration in depression patients, or finds it without any link to antidepressant response. A second independent replication would move this toward established.

Claim 2 in full
MicePreliminary

In mice, one dose drives activity-dependent structural rewiring: dendritic-spine remodeling in frontal cortex that strengthens some routes and weakens recurrent cortical loops, and that depends on the drug-evoked neural activity itself.

Would change ifAn independent lab fails to replicate activity-dependent spine remodeling, or shows the rewiring survives silencing of presynaptic input. Either would move the mechanism from preliminary to active debate.

Claim 4 in full
Healthy volunteersPreliminary

In 15 healthy adults, one dose did not significantly increase synaptic density one week later overall, measured by SV2A PET in frontal cortex and hippocampus. In an exploratory comparison, participants dosed in a therapy-like room showed a greater frontal increase than those dosed in an MRI scanner; the hippocampal difference was smaller, with an interval that included zero.

Would change ifA larger or independently replicated PET study finding a significant overall increase in synaptic density after one dose would move the human question to active debate. A preregistered test of the setting effect would show whether the subgroup difference holds.

Claim 13 in full

For teams making decisions

Request a briefing

We write a commissioned review for one compound and indication: every claim tiered and sourced, the same trust panel and method as our public syntheses, and updates when a new scan changes the picture.

  • Coverage measured against the citation graph around your question
  • Independence counted by research program, so one lab’s ten papers count once
  • What would change the conclusion, stated for every load-bearing claim
  • A weekly scan and a versioned change log when the literature moves
Biotech BD and clinical teamsPsychedelic-focused fundsClinic operatorsResearch groups

Evidence intelligence for decisions. Not medical advice.

What do you need?

Used only to answer your request. No mailing list.